Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tovecimig
- Development stage
- Phase 3
- Lead developer
- Compass Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Tovecimig is an investigational bispecific antibody designed to simultaneously block Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways. These pathways are critical for angiogenesis and tumor vascularization. By inhibiting both DLL4 and VEGF-A, tovecimig acts as a dual angiogenesis inhibitor with the potential for robust anti-tumor activity across several solid tumors. The drug has demonstrated efficacy in patients with advanced biliary tract cancer (BTC), particularly those who have progressed after first-line chemotherapy. Tovecimig is being developed by Compass Therapeutics in collaboration with ABL Bio and other partners. It is currently being evaluated in Phase II/III trials for BTC and Phase II trials for colorectal cancer[1][2][3][5][6].
- Brand names
- Tovesimig
- Other names
- tovecimig
02
Targets
Beyond the preview
Go deeper on tovecimig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tovecimig.